Axsome Therapeutics (AXSM) is down about 3.86% to $200.32 in Friday trading (May 1, 2026), a day after a major regulatory catalyst. The U.S. FDA approved an expanded use for Auvelity to treat agitation associated with dementia due to Alzheimer’s disease in adults on April 30, 2026—an outcome that drove a large one-day move higher into the close. With the binary event now resolved, the stock is giving back a portion of those gains as short-term traders de-risk and lock in profits, while others reposition ahead of the next near-term catalyst: Axsome’s first-quarter 2026 earnings on Monday, May 4, 2026. (fda.gov)

The April 30 decision expands Auvelity beyond its existing use in major depressive disorder into a new, closely watched neuropsychiatric indication tied to Alzheimer’s disease. Even when an approval is viewed as favorable, biotech and specialty pharma stocks often trade “sell-the-news” immediately after the event because expectations can become crowded into the catalyst date and the next debate shifts from approval risk to commercialization execution (coverage, utilization controls, prescriber adoption, and speed of uptake). (fda.gov)

With the label expansion secured, attention turns to how quickly the new indication translates into prescription growth and what that implies for 2026 operating spend. Monday’s Q1 report (May 4, 2026) is the next scheduled update window, and investors are likely to scrutinize: (1) any early commentary on launch preparations for the Alzheimer’s agitation indication, (2) selling and marketing investment levels, and (3) overall demand trends across Axsome’s commercial portfolio, with Auvelity remaining central to the story. (finance.yahoo.com)